Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-000294
Filing Date
2024-01-16
Accepted
2024-01-16 16:15:39
Documents
37
Period of Report
2023-11-30

Document Format Files

Seq Description Document Type Size
1 10-Q bzyr-20231130x10q.htm   iXBRL 10-Q 693652
2 EX-31.1 bzyr-20231130xex31d1.htm EX-31.1 11667
3 EX-31.2 bzyr-20231130xex31d2.htm EX-31.2 11951
4 EX-32.1 bzyr-20231130xex32d1.htm EX-32.1 6694
5 EX-32.2 bzyr-20231130xex32d2.htm EX-32.2 7124
  Complete submission text file 0001558370-24-000294.txt   2253470

Data Files

Seq Description Document Type Size
6 EX-101.SCH bzyr-20231130.xsd EX-101.SCH 17049
7 EX-101.CAL bzyr-20231130_cal.xml EX-101.CAL 17510
8 EX-101.DEF bzyr-20231130_def.xml EX-101.DEF 44322
9 EX-101.LAB bzyr-20231130_lab.xml EX-101.LAB 137616
10 EX-101.PRE bzyr-20231130_pre.xml EX-101.PRE 91277
31 EXTRACTED XBRL INSTANCE DOCUMENT bzyr-20231130x10q_htm.xml XML 210321
Mailing Address 9432 KATY FREEWAY HOUSTON TX 77055
Business Address 12000 RICHMOND AVE HOUSTON TX 77082 (713) 335-5697
BURZYNSKI RESEARCH INSTITUTE INC (Filer) CIK: 0000724445 (see all company filings)

EIN.: 760136810 | State of Incorp.: DE | Fiscal Year End: 0229
Type: 10-Q | Act: 34 | File No.: 000-23425 | Film No.: 24535328
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)